1 Min Read
March 2 (Reuters) - Merck KGaA
* Says NICE expands positive recommendation for Erbitux as first-line treatment for RAS Wild-type mCRC Source text: here$FILE/Erbitux_NICE_Eng.pdf Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.